UNSPSC 51132218: Acetaminophen/cinnamedrine/pamabrom

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132218 Acetaminophen/cinnamedrine/pamabrom is a Commodity code that in recent state and local procurement activity covers generic pharmaceuticals and over-the-counter products supplied through authorized wholesalers and direct purchase arrangements, though the code's nominal scope and actual recent solicitations show significant misalignment. The issuing bodies purchasing under or near this code span state health and human services departments (Texas HHS Commission, Minnesota Department of Administration), county health authorities (Seminole County, Florida), and multistate cooperative purchasing alliances (MMCAP, which includes Minnesota and Oregon participants). The work solicited includes annual purchases of naloxone and drug deactivation systems for community health initiatives, direct-to-manufacturer prescription fulfillment programs to improve cost management outside traditional pharmacy benefit managers, and comprehensive generic pharmaceutical and OTC product supply through established wholesaler networks with specific pricing, compliance, and delivery requirements including FDA registration, Good Manufacturing Practices certification, and Drug Supply Chain Security Act adherence.

Recent activity concentrates in Florida, Texas, and the Upper Midwest (Minnesota and Oregon through MMCAP). Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, gathering vendor capabilities for a direct-to-manufacturer prescription program outside traditional PBM and GPO channels. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with proposals due March 26, 2026, and contract effectiveness set for July 1, 2026. Award criteria in the MMCAP procurement weight price competitiveness most heavily (75 percent), with compliance and administrative fee compliance weighted at 5 percent each and fixed pricing at 10 percent. The code shows limited depth of matching activity; the Seminole County naloxone solicitation and Texas direct-manufacturer RFI address products and distribution models that do not align cleanly with the acetaminophen/cinnamedrine/pamabrom commodity scope.